CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病的免疫耐药特征与当前免疫治疗策略
英文原题：The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.
查看英文原题
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病（AML）是一种复杂的造血克隆性疾病，除干细胞移植外治愈手段有限。移植的成功与供者异体反应性免疫细胞（包括T细胞和NK细胞）介导的移植物抗白血病效应密切相关。免疫系统在白血病生存和耐药中发挥动态作用。尽管我们对免疫微环境的认识不断加深，但患者对免疫治疗的应答差异很大。本文综述了AML免疫逃逸机制的生物学，讨论了免疫治疗策略的当前格局，并探讨了治疗靶点的意义。本综述聚焦于基于T细胞和NK细胞的治疗，包括修饰和未修饰的NK细胞、CAR-T 和CAR-NK细胞、抗体以及检查点阻断。理解免疫耐受与肿瘤耐药出现之间的复杂交互将改善患者预后。
展开英文摘要原文
Acute myeloid leukemia (AML) is a complex hematopoietic clonal disorder with limited curative options beyond stem cell transplantation. The success of transplant is intimately linked with the graft versus leukemia effect from the alloreactive donor immune cells including, T and NK cells. The immune system plays a dynamic role in leukemia survival and resistance. Despite our growing understanding of the immune microenvironment, responses to immune-based therapies differ greatly between patients.
Herein, we review the biology of immune evasion mechanisms in AML, discuss the current landscape of immunotherapeutic strategies, and discuss the implications of therapeutic targets. This review focuses on T and NK cell-based therapy, including modified and non-modified NK cells, CAR-T and CAR-NK cells, antibodies, and checkpoint blockades. Understanding the complex interchange between immune tolerance and the emergence of tumor resistance will improve patient outcomes.
论文信息
- 作者
- Chandra DJ、Alber B、Saultz JN
- 单位
- Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2024 Jul 23
- 原文标识
- PubMed 39123343 · DOI 10.3390/cancers16152615
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →